330 related articles for article (PubMed ID: 15147213)
1. Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy.
Heinis C; Alessi P; Neri D
Biochemistry; 2004 May; 43(20):6293-303. PubMed ID: 15147213
[TBL] [Abstract][Full Text] [Related]
2. Prolidase, a potential enzyme target for melanoma: design of proline-containing dipeptide-like prodrugs.
Mittal S; Song X; Vig BS; Landowski CP; Kim I; Hilfinger JM; Amidon GL
Mol Pharm; 2005; 2(1):37-46. PubMed ID: 15804176
[TBL] [Abstract][Full Text] [Related]
3. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.
Wolfe LA; Mullin RJ; Laethem R; Blumenkopf TA; Cory M; Miller JF; Keith BR; Humphreys J; Smith GK
Bioconjug Chem; 1999; 10(1):38-48. PubMed ID: 9893962
[TBL] [Abstract][Full Text] [Related]
4. Prodrugs in cancer chemotherapy.
Connors TA; Knox RJ
Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
[TBL] [Abstract][Full Text] [Related]
5. Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug.
Rodrigues ML; Presta LG; Kotts CE; Wirth C; Mordenti J; Osaka G; Wong WL; Nuijens A; Blackburn B; Carter P
Cancer Res; 1995 Jan; 55(1):63-70. PubMed ID: 7805042
[TBL] [Abstract][Full Text] [Related]
6. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
Connors TA
Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
[TBL] [Abstract][Full Text] [Related]
7. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
[TBL] [Abstract][Full Text] [Related]
8. Proline prodrug of melphalan, prophalan-L, demonstrates high therapeutic index in a murine melanoma model.
Mittal S; Tsume Y; Landowski CP; Lee KD; Hilfinger JM; Amidon GL
Eur J Pharm Biopharm; 2007 Nov; 67(3):752-8. PubMed ID: 17560100
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
[TBL] [Abstract][Full Text] [Related]
10. Improved yield and stability of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineering.
McDonagh CF; Beam KS; Wu GJ; Chen JH; Chace DF; Senter PD; Francisco JA
Bioconjug Chem; 2003; 14(5):860-9. PubMed ID: 13129388
[TBL] [Abstract][Full Text] [Related]
11. Intensely cytotoxic anthracycline prodrugs: galactosides.
Bakina E; Farquhar D
Anticancer Drug Des; 1999 Dec; 14(6):507-15. PubMed ID: 10834272
[TBL] [Abstract][Full Text] [Related]
12. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
Springer CJ; Niculescu-Duvaz I
Anticancer Drug Des; 1995 Jul; 10(5):361-72. PubMed ID: 7639927
[TBL] [Abstract][Full Text] [Related]
13. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery.
Asai T; Trinh R; Ng PP; Penichet ML; Wims LA; Morrison SL
Biomol Eng; 2005 Feb; 21(6):145-55. PubMed ID: 15748688
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the tumor targeting of a FAPα-based doxorubicin prodrug.
Huang S; Fang R; Xu J; Qiu S; Zhang H; Du J; Cai S
J Drug Target; 2011 Aug; 19(7):487-96. PubMed ID: 21284542
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism.
Lu H; Waxman DJ
Mol Pharmacol; 2005 Jan; 67(1):212-9. PubMed ID: 15465924
[TBL] [Abstract][Full Text] [Related]
16. Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer.
Coelho V; Dernedde J; Petrausch U; Panjideh H; Fuchs H; Menzel C; Dübel S; Keilholz U; Thiel E; Deckert PM
Int J Oncol; 2007 Oct; 31(4):951-7. PubMed ID: 17786329
[TBL] [Abstract][Full Text] [Related]
17. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT).
Springer CJ; Antoniw P; Bagshawe KD; Wilman DE
Anticancer Drug Des; 1991 Nov; 6(5):467-79. PubMed ID: 1764165
[TBL] [Abstract][Full Text] [Related]
18. Directed evolution to improve the thermostability of prolyl endopeptidase.
Uchiyama H; Inaoka T; Ohkuma-Soyejima T; Togame H; Shibanaka Y; Yoshimoto T; Kokubo T
J Biochem; 2000 Sep; 128(3):441-7. PubMed ID: 10965043
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy.
Lengler J; Omann M; Düvier D; Holzmüller H; Gregor W; Salmons B; Günzburg WH; Renner M
Biochem Pharmacol; 2006 Sep; 72(7):893-901. PubMed ID: 16887103
[TBL] [Abstract][Full Text] [Related]
20. Virus-directed enzyme prodrug therapy using CB1954.
Grove JI; Searle PF; Weedon SJ; Green NK; McNeish IA; Kerr DJ
Anticancer Drug Des; 1999 Dec; 14(6):461-72. PubMed ID: 10834268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]